TY - JOUR
T1 - Symptom onset in autosomal dominant Alzheimer disease
T2 - A systematic review and meta-analysis
AU - Ryman, Davis C.
AU - Acosta-Baena, Natalia
AU - Aisen, Paul S.
AU - Bird, Thomas
AU - Danek, Adrian
AU - Fox, Nick C.
AU - Goate, Alison
AU - Frommelt, Peter
AU - Ghetti, Bernardino
AU - Langbaum, Jessica B.S.
AU - Lopera, Francisco
AU - Martins, Ralph
AU - Masters, Colin L.
AU - Mayeux, Richard P.
AU - McDade, Eric
AU - Moreno, Sonia
AU - Reiman, Eric M.
AU - Ringman, John M.
AU - Salloway, Steve
AU - Schofield, Peter R.
AU - Sperling, Reisa
AU - Tariot, Pierre N.
AU - Xiong, Chengjie
AU - Morris, John C.
AU - Bateman, Randall J.
PY - 2014/7/15
Y1 - 2014/7/15
N2 - Objective: To identify factors influencing age at symptom onset and disease course in autosomal dominant Alzheimer disease (ADAD), and develop evidence-based criteria for predicting symptom onset in ADAD. Methods: We have collected individual-level data on ages at symptom onset and death from 387 ADAD pedigrees, compiled from 137 peer-reviewed publications, the Dominantly Inherited Alzheimer Network (DIAN) database, and 2 large kindreds of Colombian (PSEN1 E280A) and Volga German (PSEN2 N141I) ancestry. Our combined dataset includes 3,275 individuals, of whom 1,307 were affected by ADAD with known age at symptom onset. We assessed the relative contributions of several factors in influencing age at onset, including parental age at onset, age at onset by mutation type and family, and APOE genotype and sex. We additionally performed survival analysis using data on symptom onset collected from 183 ADAD mutation carriers followed longitudinally in the DIAN Study. Results: We report summary statistics on age at onset and disease course for 174 ADAD mutations, and discover strong and highly significant (p < 10-16, r2 > 0.38) correlations between individual age at symptom onset and predicted values based on parental age at onset and mean ages at onset by mutation type and family, which persist after controlling for APOE genotype and sex. Conclusions: Significant proportions of the observed variance in age at symptom onset in ADAD can be explained by family history and mutation type, providing empirical support for use of these data to estimate onset in clinical research.
AB - Objective: To identify factors influencing age at symptom onset and disease course in autosomal dominant Alzheimer disease (ADAD), and develop evidence-based criteria for predicting symptom onset in ADAD. Methods: We have collected individual-level data on ages at symptom onset and death from 387 ADAD pedigrees, compiled from 137 peer-reviewed publications, the Dominantly Inherited Alzheimer Network (DIAN) database, and 2 large kindreds of Colombian (PSEN1 E280A) and Volga German (PSEN2 N141I) ancestry. Our combined dataset includes 3,275 individuals, of whom 1,307 were affected by ADAD with known age at symptom onset. We assessed the relative contributions of several factors in influencing age at onset, including parental age at onset, age at onset by mutation type and family, and APOE genotype and sex. We additionally performed survival analysis using data on symptom onset collected from 183 ADAD mutation carriers followed longitudinally in the DIAN Study. Results: We report summary statistics on age at onset and disease course for 174 ADAD mutations, and discover strong and highly significant (p < 10-16, r2 > 0.38) correlations between individual age at symptom onset and predicted values based on parental age at onset and mean ages at onset by mutation type and family, which persist after controlling for APOE genotype and sex. Conclusions: Significant proportions of the observed variance in age at symptom onset in ADAD can be explained by family history and mutation type, providing empirical support for use of these data to estimate onset in clinical research.
UR - http://www.scopus.com/inward/record.url?scp=84905868699&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000000596
DO - 10.1212/WNL.0000000000000596
M3 - Article
C2 - 24928124
AN - SCOPUS:84905868699
SN - 0028-3878
VL - 83
SP - 253
EP - 260
JO - Neurology
JF - Neurology
IS - 3
ER -